A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of Presumed Pre-Core Mutant Chronic Hepatitis B

Trial Profile

A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of Presumed Pre-Core Mutant Chronic Hepatitis B

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary) ; Adefovir dipivoxil
  • Indications Hepatitis B
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 03 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Nov 2015 Results regarding the evaluation of aspartate aminotransferase (AST)-to-platelet ratio index (APRI) and fibrosis index based on four factors (FIB-4) scoring systems from CHB patients enrolled in NCT00117676 and NCT00116805 published in the Journal of Hepatology.
    • 12 Apr 2015 Planned End Date changed from 1 May 2014 to 1 Jan 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top